Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 9, 2012, Pages 1002-1007

  Ha, Christina ^a   Ullman, Thomas A ^b   Siegel, Corey A ^c   Kornbluth, Asher ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Efficacious; Inflammation; Intestine; Validate

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COLON RESECTION; CROHN DISEASE; DISEASE SEVERITY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STUDY DESIGN; TERTIARY HEALTH CARE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84865335419     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.02.004     Document Type: Article

References (28)

1. Talley N.J., Abreu M.T., Achkar J.P., et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011, 106(Suppl 1):S2-S25.
2. Ford A.C., Sandborn W.J., Khan K.J., et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
3. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
4. Loftus E.V., Feagan B.G., Colombel J.F., et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008, 103:3132-3141.
5. Feagan B.G., Panaccione R., Sandborn W.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
6. Lichtiger S., Binion D.G., Wolf D.C., et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010, 32:1228-1239.
7. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
8. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
9. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
10. D'Haens G., Van Deventer S., Van Hogezand R., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
11. Targan S.R., Feagan B.G., Fedorak R.N., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007, 132:1672-1683.
12. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
13. Lichtenstein G.R., Hanauer S.B., Sandborn W.J., et al. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
14. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-523. Practice Parameters Committee of the American College of Gastroenterology.
15. Harvey R.F., Bradshaw J.M. A simple index of Crohn's disease activity. Lancet 1980, 1:514.
16. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 349:1541-1549.
17. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
18. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
19. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
20. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
21. Sokka T., Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003, 48:313-318.
22. Herland K., Akselsen J.P., Skjønsberg O.H., et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med 2005, 99:11-19.
23. Masoudi F.A., Havranek E.P., Wolfe P., et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003, 146:250-257.
24. Van Spall H.G., Toren A., Kiss A., et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007, 297:1233-1240.
25. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
26. Rothwell P.M. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005, 365:82-93.
27. Treweek S., Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009, 10:37.
28. Kingsley G.H., Khoshaba B., Smith C.M., et al. Are clinical trials in rheumatoid arthritis generalizable to routine practice?. A re-evaluation of trial entry criteria. Rheumatology (Oxford) 2005, 44:629-632.